| Autor: |
Dai Y; Non-Clinical Research & Development, Bristol Myers Squibb, Princeton, New Jersey, USA., Kavita U; Non-Clinical Research & Development, Bristol Myers Squibb, Princeton, New Jersey, USA., Lampen MH; UniQure, Amsterdam, the Netherlands; and., Gielen S; UniQure, Amsterdam, the Netherlands; and., Banks G; Cardiovascular & Fibrosis Discovery Biology, Bristol Myers Squibb, Princeton, New Jersey, USA., Levesque P; Non-Clinical Research & Development, Bristol Myers Squibb, Princeton, New Jersey, USA., Kozhich A; Non-Clinical Research & Development, Bristol Myers Squibb, Princeton, New Jersey, USA., Pillutla R; Non-Clinical Research & Development, Bristol Myers Squibb, Princeton, New Jersey, USA., Zhang Y; Non-Clinical Research & Development, Bristol Myers Squibb, Princeton, New Jersey, USA., Jawa V; Non-Clinical Research & Development, Bristol Myers Squibb, Princeton, New Jersey, USA., Adam L; Cardiovascular & Fibrosis Discovery Biology, Bristol Myers Squibb, Princeton, New Jersey, USA. |
| Abstrakt: |
Pre-existing neutralizing antibodies (NAb) to adeno-associated virus (AAV) may diminish the efficacy of AAV-based therapies depending on the titer. To support gene therapy studies in pigs, the seroprevalence of NAb to AAV1, 2, 5, 6, 8, and 9 serotypes were assessed in the sera of 3 different strains of pigs consisting of 60 Norsvin Topigs-20 strain, 22 Gottingen minipigs, and 40 Yucatan minipigs. Cell-based NAb assays were developed for various AAV serotypes. The sera were tested for NAb in a Lec-2 cell line for AAV9 vector and in a COS-7 cell line for the other AAV serotypes. In the 60 Topigs-20 strain 2 to 4 years of age, 100% were positive for AAV2 NAb, 45% positive for AAV6 NAb, and ∼20% positive for each of AAV1, 5, 8, and 9 NAb. These data showed that ∼80% of Norsvin Topigs-20 pigs evaluated were seronegative for pre-existing NAb to the AAV1, 5, 8, and 9 serotypes, respectively. In 22 Gottingen minipigs at 5-6 months of age, serum AAV serotype-specific NAb coexisted with that of various other AAV serotypes at 32% to 46% between two serotypes. These results suggested that coexisting NAb resulted either from multiple AAV serotype coinfection or from one (or more) serotypes that can crossreact with other AAV serotypes in some minipigs. Among the 40 Yucatan minipigs, 20 of the minipigs were <3 months old and were all negative for NAb against AAV5, 8, and 9, and only one of these 20 pigs was positive to AAV1 and 6. We further determined the titers in those positive pigs and found most Gottingen minipigs had low titer at 1:20, whereas some of Topigs-20 pigs had titers between 1:80 and 1:320, and some of Yucatan pigs had titers between 1:160 and 1:640. These results suggested that the majority of the pigs in the three strains would be amenable to gene therapy study using AAV1, AAV5, AAV8, and AAV9 and that prescreening on circulating AAV antibodies could be helpful before inclusion of pigs into studies. |
